| __timestamp | Halozyme Therapeutics, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 2613100000 |
| Thursday, January 1, 2015 | 29245000 | 2891500000 |
| Friday, January 1, 2016 | 33206000 | 3228800000 |
| Sunday, January 1, 2017 | 31152000 | 2966700000 |
| Monday, January 1, 2018 | 10136000 | 2900200000 |
| Tuesday, January 1, 2019 | 45546000 | 3064100000 |
| Wednesday, January 1, 2020 | 43367000 | 3248100000 |
| Friday, January 1, 2021 | 81413000 | 2722500000 |
| Saturday, January 1, 2022 | 139304000 | 2996200000 |
| Sunday, January 1, 2023 | 192361000 | 2975200000 |
| Monday, January 1, 2024 | 159417000 |
Igniting the spark of knowledge
In the ever-evolving landscape of the pharmaceutical industry, understanding cost structures is crucial. From 2014 to 2023, Halozyme Therapeutics, Inc. and Perrigo Company plc have shown distinct trajectories in their cost of revenue. Halozyme's cost of revenue surged by over 740%, from approximately $22.7 million in 2014 to $192.4 million in 2023. This reflects their aggressive expansion and investment in innovative therapies. In contrast, Perrigo's cost of revenue remained relatively stable, fluctuating around the $3 billion mark, indicating a consistent operational strategy. Notably, 2020 marked a peak for Perrigo at $3.25 billion, possibly due to increased demand for healthcare products during the pandemic. These insights highlight the contrasting strategies of a niche biotech firm versus a global healthcare giant, offering valuable lessons in financial management and strategic growth.
Cost of Revenue Trends: Amgen Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Bristol-Myers Squibb Company and Perrigo Company plc
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Perrigo Company plc
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Walgreens Boots Alliance, Inc. and Perrigo Company plc
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Perrigo Company plc's Expenses
Cost Insights: Breaking Down Alkermes plc and Perrigo Company plc's Expenses
Cost of Revenue Trends: Perrigo Company plc vs Wave Life Sciences Ltd.